Protective and Therapeutic Effects of an IL-15:IL-15Rα-Secreting Cell-Based Cancer Vaccine Using a Baculovirus System

Do-Thi, Van Anh; Lee, Hayyoung; Jeong, Hye Jin; Lee, Jie‐Oh; Kim, Young Sang

doi:10.3390/cancers13164039

Cited by 2 publications

(2 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, IL-15 was shown to promote NK-mediated antitumor response [ 25 , 26 ]. Several preclinical models and clinical trials demonstrated the ability of IL-15 to counteract HCC-induced NK dysfunction, and these findings make it a promising cytokine for cancer immunotherapy [ 27 , 28 , 29 , 30 , 31 , 32 ]. The protective, antineoplastic role of this interleukin was confirmed in our study, as, although it was detected at very low levels in both biological compartments, it was present at higher levels in patients without HCC compared to HCC patients.…”

Section: Discussionmentioning

confidence: 99%

Studies on the Role of Compartmentalized Profiles of Cytokines in the Risk of Hepatocellular Carcinoma

Fasolato,

Del Bianco,

Malacrida

et al. 2023

IJMS

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), the most common form of liver cancer, is frequently diagnosed late due to the absence of symptoms during early disease, thus heavily affecting the overall survival of these patients. Soluble immunological factors persistently produced during cirrhosis have been recognized as promoters of chronic inflammation and neoplastic transformation. The aim of this pilot study was to evaluate the predictive value of the cytokine profiles for HCC development. A Luminex xMAP approach was used for the quantification of 45 proteins in plasma and ascitic fluids of 44 cirrhotic patients without or with HCC of different etiologies. The association with patient survival was also evaluated. Univariate analyses revealed that very low levels of interleukin 5 (IL-5) (<15.86 pg/mL) in ascites and IL-15 (<12.40 pg/mL) in plasma were able to predict HCC onset with an accuracy of 81.8% and a sensitivity of 95.2%. Univariate analyses also showed that HCC, hepatitis B virus/hepatitis C virus infections, low levels of IL-5 and granulocyte-macrophage colony-stimulating factor in ascitic fluids, and high levels of eotaxin-1, hepatocyte growth factor and stromal-cell-derived factor 1α in plasma samples were factors potentially associated with a poor prognosis and decreased survival. Our results suggest a potential protective role of some immune modulators that may act in the peritoneal cavity to counteract disease progression leading to HCC development.

show abstract

Section: Discussionmentioning

confidence: 99%

Studies on the Role of Compartmentalized Profiles of Cytokines in the Risk of Hepatocellular Carcinoma

Fasolato,

Del Bianco,

Malacrida

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Additional strategies, still in preclinical development, include an autologous cell-based cancer vaccine secreting IL-15 in complex with IL-15Rα. Mice receiving inactivated cancer cells secreting IL-15:IL-15Rα had significant tumor control in both prophylactic and therapeutic cancer models ( 95 ), highlighting the promising potential of IL-15 to improve the anti-tumor response elicited by cancer vaccines.…”

Section: Il-15mentioning

confidence: 99%

Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy

Wolfarth¹,

Dhar²,

Goon³

et al. 2022

Immune Netw

View full text Add to dashboard Cite

The approval of immunotherapies such as checkpoint inhibitors (CPIs), adoptive cell therapies and cancer vaccines has revolutionized the way cancer treatment is approached. While immunotherapies have improved clinical outcome in a variety of tumor types, some cancers have proven harder to combat using single agents, underscoring the need for multi-targeted immunotherapy approaches. Efficacy of CPIs and cancer vaccines requires patients to have a competent immune system with adequate cell numbers while the efficacy of adoptive cellular therapy is limited by the expansion and persistence of cells after infusion. A promising strategy to overcome these challenges is combination treatment with common gamma-chain cytokines. Gamma-chain cytokines play a critical role in the survival, proliferation, differentiation and function of multiple immune cell types, including CD8 T-cells and NK cells, which are at the center of the anti-tumor response. While the short half-life of recombinant cytokines initially limited their application in the clinic, advancements in protein engineering have led to the development of several next-generation drug candidates with dramatically increased half-life and bioactivity. When combining these cytokines with other immunotherapies, strong evidence of synergy has been observed in preclinical and clinical cancer settings. This promising data has led to the initiation of 70 ongoing clinical trials including IL-2, IL-7, IL-15 and IL-21. This review summarizes the recent advancements of common gamma-chain cytokines and their potential as a cancer immunotherapy.

show abstract

Protective and Therapeutic Effects of an IL-15:IL-15Rα-Secreting Cell-Based Cancer Vaccine Using a Baculovirus System

Cited by 2 publications

References 61 publications

Studies on the Role of Compartmentalized Profiles of Cytokines in the Risk of Hepatocellular Carcinoma

Studies on the Role of Compartmentalized Profiles of Cytokines in the Risk of Hepatocellular Carcinoma

Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy

Contact Info

Product

Resources

About